We aim to make an impact on the lives of consumers by providing innovative and effective aesthetic solutions. We provide our customers with treatments, services and education to help their clients achieve optimal results that enhance their skin and meet their individual needs.
We have a long history of aesthetics innovation and a wealth of expertise in hyaluronic acid (HA) fillers, neuromodulators and biostimulators. Already established as the leading pure-play dermatology company, we are continuing to expand our portfolio of premium brands recommended by healthcare professionals – including Dysport®, Alluzience®, Restylane® and Sculptra®.
In line with Galderma’s ambitious goals in neuromodulation, a key pipeline clinical asset is RelabotulinumtoxinA. This product is under investigation as a novel, ready-to-use, liquid formulation of botulinum neuromodulator for the treatment of glabellar lines and lateral canthal lines. In 2023, results from Galderma’s phase IIIb trials demonstrated rapid and long-lasting effect on both.
